Hepatitis C Infographic
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
UN High-Level Meeting (HLM) on the Prevention and Control of Non-communicable Diseases (NCDs) and the Promotion of Mental Health
On 25 September 2025, IFPMA delivered a statement at the UN High-Level Meeting on NCDs and Mental Health in New York.
Read moreUN Political Declaration can accelerate action on non-communicable diseases (NCDs) and mental health
On 25 September 2025, governments discussed a Political Declaration aimed at accelerating global efforts to prevent and control NCDs and promote mental health, including through a one-third reduction of premature mortality from these conditions by 2030. Commenting on the High-Level Meeting on NCDs and Mental Health, Dr David Reddy, Director General of IFPMA, said: “The...
Read moreRevitalizing the antibiotic pipeline by implementing new R&D pull incentives
With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.
Read more